Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review.

JAMA oncology

Hauth F, Ho AY, Ferrone S, Duda DG.
PMID: 33885725
JAMA Oncol. 2021 Jul 01;7(7):1051-1059. doi: 10.1001/jamaoncol.2021.0168.

IMPORTANCE: Immunotherapy has emerged as a new pillar of cancer therapy over the past decade. Adoptive immunotherapy in particular has become a major area of research interest, with advances seen in the development of T-cell engineering. As a result,...

Cite
Hauth F, Ho AY, Ferrone S, et al. Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. JAMA Oncol. 2021;7(7):1051-1059doi: 10.1001/jamaoncol.2021.0168.
Hauth, F., Ho, A. Y., Ferrone, S., & Duda, D. G. (2021). Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. JAMA oncology, 7(7), 1051-1059. https://doi.org/10.1001/jamaoncol.2021.0168
Hauth, Franziska, et al. "Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review." JAMA oncology vol. 7,7 (2021): 1051-1059. doi: https://doi.org/10.1001/jamaoncol.2021.0168
Hauth F, Ho AY, Ferrone S, Duda DG. Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. JAMA Oncol. 2021 Jul 01;7(7):1051-1059. doi: 10.1001/jamaoncol.2021.0168. PMID: 33885725; PMCID: PMC8668197.
Copy Download .nbib Format: NLM
A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research

Lei X, Ou Z, Yang Z, Zhong J, Zhu Y, Tian J, Wu J, Deng H, Lin X, Peng Y, Li B, He L, Tu Z, Chen W, Li Q, Liu N, Zhang H, Wang Z, Fang Z, Yamada T, Lv X, Tian T, Pan G, Wu F, Xiao L, Zhang L, Cai T, Wang X, Tannous BA, Li J, Kontos F, Ferrone S, Fan S.
PMID: 33811153
Clin Cancer Res. 2021 Jul 01;27(13):3757-3771. doi: 10.1158/1078-0432.CCR-20-2487. Epub 2021 Apr 02.

PURPOSE: The limited efficacy of chimeric antigen receptor (CAR) T-cell therapies with solid malignancies prompted us to test whether epigenetic therapy could enhance the antitumor activity of B7-H3.CAR T cells with several solid cancer types.EXPERIMENTAL DESIGN: We evaluated B7-H3...

Cite
Lei X, Ou Z, Yang Z, et al. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clin Cancer Res. 2021;27(13):3757-3771doi: 10.1158/1078-0432.CCR-20-2487.
Lei, X., Ou, Z., Yang, Z., Zhong, J., Zhu, Y., Tian, J., Wu, J., Deng, H., Lin, X., Peng, Y., Li, B., He, L., Tu, Z., Chen, W., Li, Q., Liu, N., Zhang, H., Wang, Z., Fang, Z., Yamada, T., Lv, X., Tian, T., Pan, G., Wu, F., Xiao, L., Zhang, L., Cai, T., Wang, X., Tannous, B. A., Li, J., Kontos, F., Ferrone, S., & Fan, S. (2021). A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(13), 3757-3771. https://doi.org/10.1158/1078-0432.CCR-20-2487
Lei, Xinyuan, et al. "A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,13 (2021): 3757-3771. doi: https://doi.org/10.1158/1078-0432.CCR-20-2487
Lei X, Ou Z, Yang Z, Zhong J, Zhu Y, Tian J, Wu J, Deng H, Lin X, Peng Y, Li B, He L, Tu Z, Chen W, Li Q, Liu N, Zhang H, Wang Z, Fang Z, Yamada T, Lv X, Tian T, Pan G, Wu F, Xiao L, Zhang L, Cai T, Wang X, Tannous BA, Li J, Kontos F, Ferrone S, Fan S. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clin Cancer Res. 2021 Jul 01;27(13):3757-3771. doi: 10.1158/1078-0432.CCR-20-2487. Epub 2021 Apr 02. PMID: 33811153; PMCID: PMC8722110.
Copy Download .nbib Format: NLM
A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research

Lei X, Ou Z, Yang Z, Zhong J, Zhu Y, Tian J, Wu J, Deng H, Lin X, Peng Y, Li B, He L, Tu Z, Chen W, Li Q, Liu N, Zhang H, Wang Z, Fang Z, Yamada T, Lv X, Tian T, Pan G, Wu F, Xiao L, Zhang L, Cai T, Wang X, Tannous BA, Li J, Kontos F, Ferrone S, Fan S.
PMID: 33811153
Clin Cancer Res. 2021 Jul 01;27(13):3757-3771. doi: 10.1158/1078-0432.CCR-20-2487. Epub 2021 Apr 02.

PURPOSE: The limited efficacy of chimeric antigen receptor (CAR) T-cell therapies with solid malignancies prompted us to test whether epigenetic therapy could enhance the antitumor activity of B7-H3.CAR T cells with several solid cancer types.EXPERIMENTAL DESIGN: We evaluated B7-H3...

Cite
Lei X, Ou Z, Yang Z, et al. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clin Cancer Res. 2021;27(13):3757-3771doi: 10.1158/1078-0432.CCR-20-2487.
Lei, X., Ou, Z., Yang, Z., Zhong, J., Zhu, Y., Tian, J., Wu, J., Deng, H., Lin, X., Peng, Y., Li, B., He, L., Tu, Z., Chen, W., Li, Q., Liu, N., Zhang, H., Wang, Z., Fang, Z., Yamada, T., Lv, X., Tian, T., Pan, G., Wu, F., Xiao, L., Zhang, L., Cai, T., Wang, X., Tannous, B. A., Li, J., Kontos, F., Ferrone, S., & Fan, S. (2021). A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(13), 3757-3771. https://doi.org/10.1158/1078-0432.CCR-20-2487
Lei, Xinyuan, et al. "A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,13 (2021): 3757-3771. doi: https://doi.org/10.1158/1078-0432.CCR-20-2487
Lei X, Ou Z, Yang Z, Zhong J, Zhu Y, Tian J, Wu J, Deng H, Lin X, Peng Y, Li B, He L, Tu Z, Chen W, Li Q, Liu N, Zhang H, Wang Z, Fang Z, Yamada T, Lv X, Tian T, Pan G, Wu F, Xiao L, Zhang L, Cai T, Wang X, Tannous BA, Li J, Kontos F, Ferrone S, Fan S. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clin Cancer Res. 2021 Jul 01;27(13):3757-3771. doi: 10.1158/1078-0432.CCR-20-2487. Epub 2021 Apr 02. PMID: 33811153.
Copy Download .nbib Format: NLM
Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors.

Molecular therapy oncolytics

Krokhotin A, Du H, Hirabayashi K, Popov K, Kurokawa T, Wan X, Ferrone S, Dotti G, Dokholyan NV.
PMID: 31650023
Mol Ther Oncolytics. 2019 Aug 31;15:30-37. doi: 10.1016/j.omto.2019.08.008. eCollection 2019 Dec 20.

Chimeric antigen receptor (CAR)-T cell-based immunotherapy of malignant disease relies on the specificity and association constant of single-chain variable fragments (scFvs). The latter are synthesized from parent antibodies by fusing their light (V

Cite
Krokhotin A, Du H, Hirabayashi K, et al. Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors. Mol Ther Oncolytics. 2019;15:30-37doi: 10.1016/j.omto.2019.08.008.
Krokhotin, A., Du, H., Hirabayashi, K., Popov, K., Kurokawa, T., Wan, X., Ferrone, S., Dotti, G., & Dokholyan, N. V. (2019). Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors. Molecular therapy oncolytics, 1530-37. https://doi.org/10.1016/j.omto.2019.08.008
Krokhotin, Andrey, et al. "Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors." Molecular therapy oncolytics vol. 15 (2019): 30-37. doi: https://doi.org/10.1016/j.omto.2019.08.008
Krokhotin A, Du H, Hirabayashi K, Popov K, Kurokawa T, Wan X, Ferrone S, Dotti G, Dokholyan NV. Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors. Mol Ther Oncolytics. 2019 Aug 31;15:30-37. doi: 10.1016/j.omto.2019.08.008. eCollection 2019 Dec 20. PMID: 31650023; PMCID: PMC6804740.
Copy Download .nbib Format: NLM
NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo.

Cancers

Vallera DA, Ferrone S, Kodal B, Hinderlie P, Bendzick L, Ettestad B, Hallstrom C, Zorko NA, Rao A, Fujioka N, Ryan CJ, Geller MA, Miller JS, Felices M.
PMID: 32961861
Cancers (Basel). 2020 Sep 18;12(9). doi: 10.3390/cancers12092659.

We improved the bispecific antibody platform that primarily engages natural killer (NK) cells to kill cancer cells through antibody-dependent cellular cytotoxicity (ADCC) by adding IL-15 as a crosslinker that expands and self-sustains the effector NK cell population. The overall...

Cite
Vallera DA, Ferrone S, Kodal B, et al. NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers (Basel). 2020;12(9)doi: 10.3390/cancers12092659.
Vallera, D. A., Ferrone, S., Kodal, B., Hinderlie, P., Bendzick, L., Ettestad, B., Hallstrom, C., Zorko, N. A., Rao, A., Fujioka, N., Ryan, C. J., Geller, M. A., Miller, J. S., & Felices, M. (2020). NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers, 12(9), . https://doi.org/10.3390/cancers12092659
Vallera, Daniel A, et al. "NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo." Cancers vol. 12,9 (2020). doi: https://doi.org/10.3390/cancers12092659
Vallera DA, Ferrone S, Kodal B, Hinderlie P, Bendzick L, Ettestad B, Hallstrom C, Zorko NA, Rao A, Fujioka N, Ryan CJ, Geller MA, Miller JS, Felices M. NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers (Basel). 2020 Sep 18;12(9). doi: 10.3390/cancers12092659. PMID: 32961861; PMCID: PMC7564091.
Copy Download .nbib Format: NLM
B7-H3: An Attractive Target for Antibody-based Immunotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research

Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, Ferrone S.
PMID: 33051306
Clin Cancer Res. 2021 Mar 01;27(5):1227-1235. doi: 10.1158/1078-0432.CCR-20-2584. Epub 2020 Oct 13.

The recent impressive clinical responses to antibody-based immunotherapy have prompted the identification of clinically relevant tumor antigens that can serve as targets in solid tumors. Among them, B7-H3, a member of the B7 ligand family, represents an attractive target...

Cite
Kontos F, Michelakos T, Kurokawa T, et al. B7-H3: An Attractive Target for Antibody-based Immunotherapy. Clin Cancer Res. 2020;27(5):1227-1235doi: 10.1158/1078-0432.CCR-20-2584.
Kontos, F., Michelakos, T., Kurokawa, T., Sadagopan, A., Schwab, J. H., Ferrone, C. R., & Ferrone, S. (2021). B7-H3: An Attractive Target for Antibody-based Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(5), 1227-1235. https://doi.org/10.1158/1078-0432.CCR-20-2584
Kontos, Filippos, et al. "B7-H3: An Attractive Target for Antibody-based Immunotherapy." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,5 (2021): 1227-1235. doi: https://doi.org/10.1158/1078-0432.CCR-20-2584
Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, Ferrone S. B7-H3: An Attractive Target for Antibody-based Immunotherapy. Clin Cancer Res. 2021 Mar 01;27(5):1227-1235. doi: 10.1158/1078-0432.CCR-20-2584. Epub 2020 Oct 13. PMID: 33051306; PMCID: PMC7925343.
Copy Download .nbib Format: NLM
Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research

Lichtman EI, Du H, Shou P, Song F, Suzuki K, Ahn S, Li G, Ferrone S, Su L, Savoldo B, Dotti G.
PMID: 33531429
Clin Cancer Res. 2021 Jun 01;27(11):3141-3153. doi: 10.1158/1078-0432.CCR-20-2540. Epub 2021 Feb 02.

PURPOSE: The development of safe and effective chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) has largely been limited by the concomitant expression of most AML-associated surface antigens on normal myeloid progenitors and by the potential...

Cite
Lichtman EI, Du H, Shou P, et al. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res. 2021;27(11):3141-3153doi: 10.1158/1078-0432.CCR-20-2540.
Lichtman, E. I., Du, H., Shou, P., Song, F., Suzuki, K., Ahn, S., Li, G., Ferrone, S., Su, L., Savoldo, B., & Dotti, G. (2021). Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(11), 3141-3153. https://doi.org/10.1158/1078-0432.CCR-20-2540
Lichtman, Eben I, et al. "Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,11 (2021): 3141-3153. doi: https://doi.org/10.1158/1078-0432.CCR-20-2540
Lichtman EI, Du H, Shou P, Song F, Suzuki K, Ahn S, Li G, Ferrone S, Su L, Savoldo B, Dotti G. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res. 2021 Jun 01;27(11):3141-3153. doi: 10.1158/1078-0432.CCR-20-2540. Epub 2021 Feb 02. PMID: 33531429; PMCID: PMC8248479.
Copy Download .nbib Format: NLM
Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells.

Cancers

Peppicelli S, Ruzzolini J, Andreucci E, Bianchini F, Kontos F, Yamada T, Ferrone S, Calorini L.
PMID: 31454998
Cancers (Basel). 2019 Aug 26;11(9). doi: 10.3390/cancers11091249.

Besides playing a crucial role in immune surveillance, human leukocyte antigens (HLA) possess numerous non-immune functions involved in cell communication. In the present study, screening of a panel of HLA class I- and HLA class II-specific monoclonal antibodies (mAbs)...

Cite
Peppicelli S, Ruzzolini J, Andreucci E, et al. Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells. Cancers (Basel). 2019;11(9)doi: 10.3390/cancers11091249.
Peppicelli, S., Ruzzolini, J., Andreucci, E., Bianchini, F., Kontos, F., Yamada, T., Ferrone, S., & Calorini, L. (2019). Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells. Cancers, 11(9), . https://doi.org/10.3390/cancers11091249
Peppicelli, Silvia, et al. "Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells." Cancers vol. 11,9 (2019). doi: https://doi.org/10.3390/cancers11091249
Peppicelli S, Ruzzolini J, Andreucci E, Bianchini F, Kontos F, Yamada T, Ferrone S, Calorini L. Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells. Cancers (Basel). 2019 Aug 26;11(9). doi: 10.3390/cancers11091249. PMID: 31454998; PMCID: PMC6770395.
Copy Download .nbib Format: NLM
A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research

Lei X, Ou Z, Yang Z, Zhong J, Zhu Y, Tian J, Wu J, Deng H, Lin X, Peng Y, Li B, He L, Tu Z, Chen W, Li Q, Liu N, Zhang H, Wang Z, Fang Z, Yamada T, Lv X, Tian T, Pan G, Wu F, Xiao L, Zhang L, Cai T, Wang X, Tannous BA, Li J, Kontos F, Ferrone S, Fan S.
PMID: 33811153
Clin Cancer Res. 2021 Jul 01;27(13):3757-3771. doi: 10.1158/1078-0432.CCR-20-2487. Epub 2021 Apr 02.

PURPOSE: The limited efficacy of chimeric antigen receptor (CAR) T-cell therapies with solid malignancies prompted us to test whether epigenetic therapy could enhance the antitumor activity of B7-H3.CAR T cells with several solid cancer types.EXPERIMENTAL DESIGN: We evaluated B7-H3...

Cite
Lei X, Ou Z, Yang Z, et al. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clin Cancer Res. 2021;27(13):3757-3771doi: 10.1158/1078-0432.CCR-20-2487.
Lei, X., Ou, Z., Yang, Z., Zhong, J., Zhu, Y., Tian, J., Wu, J., Deng, H., Lin, X., Peng, Y., Li, B., He, L., Tu, Z., Chen, W., Li, Q., Liu, N., Zhang, H., Wang, Z., Fang, Z., Yamada, T., Lv, X., Tian, T., Pan, G., Wu, F., Xiao, L., Zhang, L., Cai, T., Wang, X., Tannous, B. A., Li, J., Kontos, F., Ferrone, S., & Fan, S. (2021). A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(13), 3757-3771. https://doi.org/10.1158/1078-0432.CCR-20-2487
Lei, Xinyuan, et al. "A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,13 (2021): 3757-3771. doi: https://doi.org/10.1158/1078-0432.CCR-20-2487
Lei X, Ou Z, Yang Z, Zhong J, Zhu Y, Tian J, Wu J, Deng H, Lin X, Peng Y, Li B, He L, Tu Z, Chen W, Li Q, Liu N, Zhang H, Wang Z, Fang Z, Yamada T, Lv X, Tian T, Pan G, Wu F, Xiao L, Zhang L, Cai T, Wang X, Tannous BA, Li J, Kontos F, Ferrone S, Fan S. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clin Cancer Res. 2021 Jul 01;27(13):3757-3771. doi: 10.1158/1078-0432.CCR-20-2487. Epub 2021 Apr 02. PMID: 33811153.
Copy Download .nbib Format: NLM
Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review.

JAMA oncology

Hauth F, Ho AY, Ferrone S, Duda DG.
PMID: 33885725
JAMA Oncol. 2021 Jul 01;7(7):1051-1059. doi: 10.1001/jamaoncol.2021.0168.

IMPORTANCE: Immunotherapy has emerged as a new pillar of cancer therapy over the past decade. Adoptive immunotherapy in particular has become a major area of research interest, with advances seen in the development of T-cell engineering. As a result,...

Cite
Hauth F, Ho AY, Ferrone S, et al. Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. JAMA Oncol. 2021;7(7):1051-1059doi: 10.1001/jamaoncol.2021.0168.
Hauth, F., Ho, A. Y., Ferrone, S., & Duda, D. G. (2021). Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. JAMA oncology, 7(7), 1051-1059. https://doi.org/10.1001/jamaoncol.2021.0168
Hauth, Franziska, et al. "Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review." JAMA oncology vol. 7,7 (2021): 1051-1059. doi: https://doi.org/10.1001/jamaoncol.2021.0168
Hauth F, Ho AY, Ferrone S, Duda DG. Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. JAMA Oncol. 2021 Jul 01;7(7):1051-1059. doi: 10.1001/jamaoncol.2021.0168. PMID: 33885725; PMCID: PMC8668197.
Copy Download .nbib Format: NLM
Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research

Lichtman EI, Du H, Shou P, Song F, Suzuki K, Ahn S, Li G, Ferrone S, Su L, Savoldo B, Dotti G.
PMID: 33531429
Clin Cancer Res. 2021 Jun 01;27(11):3141-3153. doi: 10.1158/1078-0432.CCR-20-2540. Epub 2021 Feb 02.

PURPOSE: The development of safe and effective chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) has largely been limited by the concomitant expression of most AML-associated surface antigens on normal myeloid progenitors and by the potential...

Cite
Lichtman EI, Du H, Shou P, et al. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res. 2021;27(11):3141-3153doi: 10.1158/1078-0432.CCR-20-2540.
Lichtman, E. I., Du, H., Shou, P., Song, F., Suzuki, K., Ahn, S., Li, G., Ferrone, S., Su, L., Savoldo, B., & Dotti, G. (2021). Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(11), 3141-3153. https://doi.org/10.1158/1078-0432.CCR-20-2540
Lichtman, Eben I, et al. "Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,11 (2021): 3141-3153. doi: https://doi.org/10.1158/1078-0432.CCR-20-2540
Lichtman EI, Du H, Shou P, Song F, Suzuki K, Ahn S, Li G, Ferrone S, Su L, Savoldo B, Dotti G. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res. 2021 Jun 01;27(11):3141-3153. doi: 10.1158/1078-0432.CCR-20-2540. Epub 2021 Feb 02. PMID: 33531429; PMCID: PMC8248479.
Copy Download .nbib Format: NLM
A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research

Lei X, Ou Z, Yang Z, Zhong J, Zhu Y, Tian J, Wu J, Deng H, Lin X, Peng Y, Li B, He L, Tu Z, Chen W, Li Q, Liu N, Zhang H, Wang Z, Fang Z, Yamada T, Lv X, Tian T, Pan G, Wu F, Xiao L, Zhang L, Cai T, Wang X, Tannous BA, Li J, Kontos F, Ferrone S, Fan S.
PMID: 33811153
Clin Cancer Res. 2021 Jul 01;27(13):3757-3771. doi: 10.1158/1078-0432.CCR-20-2487. Epub 2021 Apr 02.

PURPOSE: The limited efficacy of chimeric antigen receptor (CAR) T-cell therapies with solid malignancies prompted us to test whether epigenetic therapy could enhance the antitumor activity of B7-H3.CAR T cells with several solid cancer types.EXPERIMENTAL DESIGN: We evaluated B7-H3...

Cite
Lei X, Ou Z, Yang Z, et al. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clin Cancer Res. 2021;27(13):3757-3771doi: 10.1158/1078-0432.CCR-20-2487.
Lei, X., Ou, Z., Yang, Z., Zhong, J., Zhu, Y., Tian, J., Wu, J., Deng, H., Lin, X., Peng, Y., Li, B., He, L., Tu, Z., Chen, W., Li, Q., Liu, N., Zhang, H., Wang, Z., Fang, Z., Yamada, T., Lv, X., Tian, T., Pan, G., Wu, F., Xiao, L., Zhang, L., Cai, T., Wang, X., Tannous, B. A., Li, J., Kontos, F., Ferrone, S., & Fan, S. (2021). A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(13), 3757-3771. https://doi.org/10.1158/1078-0432.CCR-20-2487
Lei, Xinyuan, et al. "A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,13 (2021): 3757-3771. doi: https://doi.org/10.1158/1078-0432.CCR-20-2487
Lei X, Ou Z, Yang Z, Zhong J, Zhu Y, Tian J, Wu J, Deng H, Lin X, Peng Y, Li B, He L, Tu Z, Chen W, Li Q, Liu N, Zhang H, Wang Z, Fang Z, Yamada T, Lv X, Tian T, Pan G, Wu F, Xiao L, Zhang L, Cai T, Wang X, Tannous BA, Li J, Kontos F, Ferrone S, Fan S. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clin Cancer Res. 2021 Jul 01;27(13):3757-3771. doi: 10.1158/1078-0432.CCR-20-2487. Epub 2021 Apr 02. PMID: 33811153; PMCID: PMC8722110.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries